G. KAVGACI Et Al. , "Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer," Anti-cancer drugs , vol.35, no.5, pp.459-461, 2024
KAVGACI, G. Et Al. 2024. Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer. Anti-cancer drugs , vol.35, no.5 , 459-461.
KAVGACI, G., Dizdar, O., & Yalcin, S., (2024). Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer. Anti-cancer drugs , vol.35, no.5, 459-461.
KAVGACI, GÖZDE, Omer Dizdar, And Suayib Yalcin. "Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer," Anti-cancer drugs , vol.35, no.5, 459-461, 2024
KAVGACI, GÖZDE Et Al. "Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer." Anti-cancer drugs , vol.35, no.5, pp.459-461, 2024
KAVGACI, G. Dizdar, O. And Yalcin, S. (2024) . "Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer." Anti-cancer drugs , vol.35, no.5, pp.459-461.
@article{article, author={GÖZDE KAVGACI Et Al. }, title={Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer}, journal={Anti-cancer drugs}, year=2024, pages={459-461} }